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Abstract
Background: The prostaglandin E2 EP2 receptor has been shown to be important in dictating outcomes in various 
neuroinflammatory disorders. Here, we investigated the importance of the EP2 receptor in short- and long-term 
ischemic outcomes by subjecting wildtype (WT) and EP2 knockout (EP2-/-) mice to two distinct and complementary 
stroke models [transient and permanent middle cerebral artery occlusion (tMCAO and pMCAO)] and by using the EP2 
receptor agonist ONO-AE1-259-01.
Methods: First, WT and EP2-/- mice were subjected to 90-min tMCAO with a monofilament followed by 4-day 
reperfusion. Second, WT mice were infused intracerebroventricularly with vehicle or ONO-AE1-259-01 45-50 min 
before being subjected to tMCAO. Finally, WT and EP2-/- mice were subjected to pMCAO and allowed to survive for an 
extended period of 7 days.
Results: Infarct volumes in EP2-/- mice were 55.0 ± 9.1% larger after tMCAO and 33.3 ± 8.6% larger after pMCAO than 
those in WT mice. Neurobehavioral deficits also were significantly greater in the EP2-/- mice. These results suggest that 
EP2 is beneficial and that activation is sustained for days after the stroke. We also found that pharmacologic activation 
of EP2 with 1.0- and 2.0-nmol doses of ONO-AE1-259-01 was sufficient to significantly reduce the infarct volume in WT 
mice compared with that in vehicle-treated controls (20.1 ± 3.9% vs. 37.1 ± 4.6%). This reduction correlated with 
improved neurologic scores. No significant effect on physiologic parameters was observed.
Conclusion: Together, our results reveal that pharmacologic stimulation of the EP2 receptor has an important 
beneficial role in cerebral ischemia and might be considered as an adjunct therapy for ischemic stroke.
Introduction
Prostaglandin E2 (PGE2), formed from arachidonic acid
by the action of cyclooxygenases and PGE2 synthases, was
previously considered to be a pro-inflammatory prosta-
glandin, but it may have a much more complex role. PGE2
executes its functions by binding mainly to four mem-
brane-bound G-protein-coupled receptors known as E-
prostanoid (EP) 1, 2, 3, and 4. These EP receptors have
varied effects on cyclic adenosine monophosphate
(cAMP) production, phosphoinositol turnover, and intra-
cellular calcium level regulation [1]. The EP1 receptor
increases levels of intracellular calcium [2]. The EP3
receptor, which has several isoforms and consequently
couples to several different G-proteins, elicits varied sig-
naling pathways that lead to changes in cAMP levels, cal-
cium mobilization, and activation of phospholipase C [3].
The EP2 and EP4 receptors, which increase the intracel-
lular levels of cAMP, work via a G-protein-coupled mech-
anism that stimulates adenylyl cyclase [4-6].
I n  m i c e ,  t h e  E P 2  r e c e p t o r  h a s  b e e n  r e p o r t e d  t o  b e
highly expressed in cerebral cortex, striatum, and hip-
pocampus [7,8]. Genetic knockout of this receptor signif-
icantly increases lesion volume at the 24-h time point in
mice subjected to ischemic paradigms, with no apparent
change in behavior [9,10]. It is important to understand
the etiopathology of stroke damage and especially its
inflammatory cascade over time. Therefore, our goal was
to determine whether the anatomical protective effects of
EP2 activation are sustained over time (and are not only
transient or delayed) and whether such changes correlate
with neurologic improvements.
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Furthermore, even though previous studies that used
EP2 knockout (EP2-/-) mice reported that the presence of
EP2 is beneficial in ischemic stroke in vivo, none has
demonstrated that EP2 stimulation indeed limits infarct
damage. To test this paradigm, we investigated whether
the highly selective EP2 agonist ONO-AE1-259-01 could
reduce ischemic brain damage in C57BL/6 WT mice.
ONO-AE1-259-01 has no detectable affinity to any other
prostaglandin receptor [11] and binds with higher affinity
to the EP2 receptor (Ki = 3 nM) than does PGE1, 16,16-
dimethyl-PGE2, 11-deoxy-PGE1, butaprost, or AH-6809
(Ki = 10, 17, 45, 110, and 350 nM, respectively) [5,6,12].
Materials and methods
Animals and Treatments
These studies were carried out in male C57BL/6 mice (25
to 30 g) purchased from Charles River Laboratories, Inc
(Wilmington, MA). The EP2-/- mouse colony was main-
tained in the Johns Hopkins animal facility. Animal pro-
tocols for these studies were approved by the Johns
Hopkins University Animal Care and Use Committee.
The animals were allowed free access to water and food
before and after surgery. ONO-AE1-259-01 [(16S)-9-
deoxy-9beta-chloro-15-deoxy-16-hydroxy-17,17-trim-
ethylene-19,20-didehydro-PGE2  sodium salt] was pro-
vided by Ono Pharmaceutical Co. Ltd.
Cerebral Vessel Diameter and Anatomy
To determine the large cerebral vessel gross anatomy in
WT and EP2-/- mice, three naïve mice of each genotype
were anesthetized deeply and perfused via the heart left
ventricle with 5 mL of ice-cold saline followed by 1 mL of
black latex paint. Then the mice were decapitated and
their brains removed with the circle of Willis intact. The
brains were placed in 10% formalin for 24 h before exam-
ination with MetaVue software (Meta Imaging Series
Software, Downingtown, PA).
Experimental Design and Drug Injection
In this study, three sets of experiments were performed.
In the first experiment, WT (n = 9) and EP2-/- (n = 14)
mice were subjected to 90 min of transient middle cere-
bral artery occlusion (tMCAO) and 96 h of reperfusion.
In the second experiment, WT mice (n = 9/group) were
given intracerebroventricular injections of ONO-AE1-
259-01 (0.5, 1.0, 2.0 nmol) or vehicle (water) 45-50 min
b e f o r e  t M C A O .  B r i e f l y ,  m i c e  w e r e  a n e s t h e t i z e d  a n d
mounted on a stereotaxic frame, the skull was exposed
under aseptic conditions, and a hole was drilled accord-
ing to the coordinates: anteroposterior, 0.5 mm; lateral,
1.0 mm from the bregma; and ventral, 2.5 mm relative to
the dura. ONO-AE1-259-01 or vehicle was injected in a
volume of 0.2 μL into the right lateral ventricle; the nee-
dle was left in place for 10 min before being slowly
retracted. Finally, the hole was blocked, and the skin over-
lying the skull was sutured. Mice were then prepared for
tMCAO surgery as described below. Physiologic studies
were carried out in a separate cohort of correspondingly
treated EP2-/- and ONO-AE1-259-01-treated mice. In the
third experiment, WT (n = 8) and EP2-/- (n = 7) mice were
subjected to distal permanent middle cerebral artery
occlusion (pMCAO).
Transient Focal Cerebral Ischemia (tMCAO) and 
Reperfusion
Transient focal cerebral ischemia was induced by occlu-
sion of the middle cerebral artery (MCA) with an intralu-
minal filament, as described previously [13]. Each mouse
was maintained with continuous-flow 1.0-1.5% halothane
(after induction with 3.0% halothane) in oxygen-enriched
air via a nose cone. The core body temperature (rectal)
was maintained at 37.0 ± 0.5°C by a heating pad. No dif-
ferences in rectal temperature between genotypes were
noted before, during, or immediately after ischemia. Rel-
ative cerebral blood flow (CBF) was measured by laser-
Doppler flowmetry (Moor Instruments, Devon, England)
with a flexible fiberoptic probe affixed to the skull over
the parietal cortex supplied by the MCA (2 mm posterior
and 6 mm lateral to the bregma). Under aseptic condi-
tions, the neck and carotid bifurcation were dissected,
and the common carotid artery was temporarily ligated.
A 7-0 Ethilon nylon monofilament (Ethicon, Inc., Somer-
ville, NJ) coated with flexible silicone (Cutter Sil light uni-
versal hardener, Heraeus Kulzer GmbH, Hanau,
Germany) was inserted to occlude the MCA. The fila-
ment was advanced through an incision in the external
carotid artery stump, through the internal carotid artery
to the origin of the MCA; successful occlusion was docu-
mented by a decrease in laser-Doppler signal of at least
80%. The filament was left in position for 90 min. During
occlusion, the neck was closed with sutures, anesthesia
was discontinued, and the animals were transferred to a
temperature-controlled chamber to maintain the body
temperature at 37.0 ± 0.5°C. At 90 min of occlusion, the
mouse was briefly re-anesthetized with halothane, and
reperfusion was achieved by slowly withdrawing the fila-
ment. After its neck was sutured, the mouse was again
placed in the temperature-controlled chamber for 2 h and
then returned to its home cage for 4 days. The 4-day time
point was selected because it allows maximal survival fol-
lowing the tMCAO.
Permanent Distal Middle Cerebral Artery Occlusion 
(pMCAO)
Permanent MCAO studies were carried out by the
method of Majid et al. [14,15] with minor modifications.
This permanent distal ischemic protocol was selected
because it is highly reproducible and it affects mainly theAhmad et al. Experimental & Translational Stroke Medicine 2010, 2:12
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cortical region, whereas the transient ischemic model
causes striatal damage that then extends to the cortical
region. The permanent model also allows the study of
more distal time points (as described below). Briefly,
mice were anesthetized with halothane, and a 1.0-cm ver-
tical skin incision was made between the right eye and
ear. The temporal muscle was moved aside to expose the
temporal bone. Under a surgical microscope, a 2.0-mm
burr hole was drilled over the MCA, transparently visible
through the temporal bone. The distal part of the MCA
was occluded with a bipolar coagulator, and complete
interruption of blood flow at the occlusion site was con-
firmed by severance of the occlusion site of the MCA.
Core body temperature was maintained between 36.5 and
37.5°C during and after the procedure. Animals not cir-
cling toward the paretic side after the onset of ischemia
and those that developed subarachnoid hemorrhage were
eliminated from the study. The successful occlusion was
confirmed by placing the laser-Doppler probe above the
temporal ridge to establish that blood flow into the region
was stopped. At 7 days, mice were euthanized and the
brains sectioned. The 7-day time point was selected
rather than the 24-h time point because it allows time for
extended permanent ischemic damage and can be
achieved with 100% survival.
Assessment of Neurologic Function and Physiologic 
Parameters
Mice subjected to tMCAO were evaluated for neurologic
deficit via a 5-point scale after 96 h of reperfusion. The
scores were recorded as: 0, no deficit; 1, forelimb weak-
ness and torso turning to the ipsilateral side when held by
the tail; 2, circling to the affected side; 3, unable to bear
weight on the affected side; and 4, no spontaneous loco-
motor activity, according to the protocol used in our pre-
vious studies [13,15-17,19]. In a separate cohort,
physiologic parameters were measured before occlusion,
during occlusion, and during reperfusion. A catheter was
inserted into the femoral artery and attached to an auto-
mated blood pressure monitor to measure mean arterial
blood pressure (MABP). At regular intervals, blood sam-
ples were collected through the catheter for analysis of
pH, PaO2, and PaCO2.
Mice subjected to pMCAO were tested for neurologic
deficits 7 days after occlusion by an experimenter blinded
to the mouse genotype according to a 28-point scoring
system [15,20]. Since the pMCAO lesion is distinct from
that which occurs with the tMCAO model, we have opti-
mized a neurobehavioral test that enables us to look for
subtle and reproducible differences between groups. The
tests included assessments of body symmetry, gait, climb-
ing, circling behavior, front limb symmetry, compulsory
circling, and whisker response. Each test was graded from
0 to 4, establishing a maximum deficit score of 28. Imme-
diately after the testing, the mice were sacrificed for
infarct volume analysis.
Quantification of Infarct Volumes
After tMCAO and pMCAO, mice were deeply anesthe-
tized, and brains were harvested and cooled in a deep
freezer. Five coronal sections of 2-mm thickness were cut
and then incubated in 2% 2,3,5-triphenyl-tetrazolium
chloride (TTC) in saline for 20 min at 37°C. The area of
infarct, which remains white, was measured on the ros-
tral and caudal surfaces of all five slices and numerically
integrated across the thickness of the slice to obtain an
estimate of infarct volume (SigmaScan Pro, SPSS Inc.
Port Richmond, CA). Infarct volume was converted by
multiplying the measured infarct volume by the ratio of
the contralateral structure to the ipsilateral structure [21].
Statistics
Data, expressed as mean ± SEM, were analyzed by
ANOVA and when appropriate, Newman-Keuls multiple
range test. Statistical significance was set at P < 0.05.
Results
Comparison of Cerebrovascular Anatomy in WT and EP2-/- 
Mice
We evaluated the gross cerebrovascular anatomy by mea-
suring the large vessel diameters in the brains of WT and
EP2-/- mice and found no significant differences between
the two genotypes (Figure 1). This observation suggested
that there are no obvious changes in blood vessel diame-
ters of these mice under this experimental design. This
knowledge made us confident to pursue the following
ischemic stroke paradigms.
Effect of EP2 Receptor Genetic Deletion on Monitored 
Physiologic Parameters of Mice Subjected to tMCAO
No significant differences in blood gases (PaO2, PaCO2,
pH) were noted between WT and EP2-/- mice at baseline,
Figure 1 Genetic deletion of the EP2 receptor does not signifi-
cantly alter gross vascular anatomy of the brain. Macroscopic anal-
ysis of cerebral arterial vasculature revealed no differences in the circle 
of Willis or major cerebral arteries between EP2-/- and WT mice (n = 3/
group).
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1 h after tMCAO, or 1 h after reperfusion (Table 1). The
relative CBF dropped more than 80% from baseline after
tMCAO and returned to near baseline after reperfusion
in WT and EP2-/- mice (Figure 2). Our data suggest an
immediate reperfusion after removal of the filament,
whereas a previous report documented a slower recovery
that could have potentially affected the stroke outcomes
[9]. Overall, no significant differences in CBF, body tem-
perature, or MABP were observed between the two geno-
types before, during, or after tMCAO.
Effect of EP2 Receptor Genetic Deletion on Neurologic 
Scores and Infarct Volume after tMCAO
The neurologic deficit scores of EP2-/- mice were signifi-
cantly (P < 0.01) higher than those of WT mice after 90-
min tMCAO and 4-day reperfusion (Figure 3). Further-
more, according to the TTC-staining method, EP2-/- mice
had a significantly larger mean infarct size (P < 0.01) than
that of their WT counterparts after tMCAO (Figure 3).
The percent mortality was estimated at 36% in EP2-/-
mice (14 of 22 survived) and 25% in WT mice (9 of 12
survived).
Effect of the EP2-selective Agonist ONO-AE1-259-01 on 
Physiologic Parameters of Mice Subjected to tMCAO
The blood gas (pH, PaCO2, PaO2) concentrations in vehi-
cle- and ONO-AE1-259-01-treated groups (n = 5/group)
remained within normal physiologic ranges, and no sig-
nificant differences were measured between the groups.
Similarly, the MABP did not differ significantly between
the groups (Table 2). As estimated by laser-Doppler flow-
metry, the relative CBF rapidly decreased to more than
80% below baseline in both vehicle- and ONO-AE1-259-
01-treated groups. The percent reduction in CBF did not
differ significantly between the groups.
ONO-AE1-259-01 Attenuates Neurologic Dysfunction and 
Infarct Volume in Mice Subjected to tMCAO
Although we and others have shown that deletion of EP2
is detrimental to stroke outcome, here we wanted to test
whether the use of a selective agonist would provide pro-
tection. The neurologic deficits in the groups adminis-
tered 1.0 and 2.0 nmol of ONO-AE1-259-01 before
tMCAO were significantly less severe than those of the
vehicle-treated group; no difference was observed in the
group given the lowest dose of 0.5 nmol (Figure 4). Fur-
thermore, the ONO-AE1-259-01-treated groups had sig-
nificantly (P  < 0.05) attenuated hemispheric infarct
volumes at the 1.0- and 2.0-nmol doses compared with
Table 1: Physiologic Parameters in WT and EP2-/- Mice
Parameter WT Mice EP2-/- Mice
Baseline 1 h MCAO 1 h Reperfusion Baseline 1 h MCAO 1 h Reperfusion
pH 7.37 ± 0.02 7.34 ± 0.02 7.35 ± 0.01 7.32 ± 0.01 7.33 ± 0.01 7.33 ± 0.01
PaCO2 38.2 ± 1.4 40.0 ± 1.5 38.7 ± 1.5 42.5 ± 1.3 41.2 ± 2.2 41.4 ± 1.0
PaO2 113 ± 6 131 ± 3 121 ± 9 127 ± 3 124 ± 5 120 ± 4
Measurements were made in arterial blood samples obtained via femoral catheter. WT, n = 4; EP2-/-, n = 5.
Figure 2 Genetic deletion of the EP2 receptor does not affect 
physiologic parameters. Relative cerebral blood flow (CBF, A), core 
body temperature (B), and mean arterial blood pressure (MABP, C) 
were recorded at baseline, at induction of ischemia, and at 15-min in-
tervals during ischemia and 1 h of reperfusion in WT and EP2-/- mice (n 
= 4 WT and 5 EP2-/-). The change in CBF was recorded as a percent of 
baseline.
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the vehicle-treated group, but the lowest dose did not
reach significance (Figure 4). In mice treated with ONO-
AE1-259-01, the percent mortality was estimated at 30%
at the dose of 0.05 nmol (9 of 13 survived), 30% at 1.0
nmol (9 of 13 survived), and 25% at 2.0 nmol (9 of 12 sur-
vived) compared with 36% in the vehicle-treated group (9
of 14 survived).
Effect of EP2 Receptor Genetic Deletion on Neurologic 
Deficits and Infarct Volume in Mice Subjected to pMCAO
To address whether ischemic outcomes could differ in
different ischemic stroke models, we compared outcomes
obtained from the transient ischemic reperfusion model
(as represented in Figure 3) with those of the permanent
ischemic model. The transient model is characterized by
an ischemic-reperfusion injury that results consistently in
damage that begins mostly in the striatum and then
spreads especially to the surrounding cortical region. In
contrast, the permanent distal occlusion model does not
have the reperfusion injury component, and it results in a
brain lesion mainly constrained within the cortex. Thus,
these two models are complementary. In addition to
addressing different ischemic stroke paradigms, their
outcomes are also regionally dependent. Finally, whereas
others have studied early time points after stroke, namely
24 h [10], we assessed outcomes at 7 days after pMCAO.
We found that at 7 days after pMCAO, EP2-/- mice suf-
fered significantly greater neurologic deficits than did
WT mice (P < 0.04) and had significantly larger infarct
volumes than did their WT counterparts (P < 0.008; Fig-
ure 5). No mortality was observed after distal permanent
focal cerebral ischemia in either genotype.
Discussion
This study was designed to further ascertain the unique
neuroprotective properties of the PGE2 EP2 receptor in
ischemic stroke. Using EP2-/- mice, we showed that the
EP2 receptor is protective in cortical and striatal brain
regions affected by tMCAO and in the cortex after
pMCAO but that its deletion does not affect the gross
cerebrovascular anatomy or the physiologic parameters
of blood pH, PaO2, PaCO2, or MABP. We also demon-
strated that this protective action of EP2 receptors is not
simply transient or acute, as previously suggested, but
lasts for days. Furthermore, pretreatment of mice with
1.0- and 2.0-nmol doses of the highly selective EP2 recep-
tor agonist ONO-AE1-259-01 significantly reduced the
infarct volume induced by transient ischemia, again with-
out affecting the physiologic parameters monitored.
These results clearly demonstrate that pharmacologic
stimulation of the EP2 receptors in the brain attenuates
brain damage caused by cerebral ischemia and support
the hypothesis that EP2 receptor stimulation is important
throughout an extended duration of the pathophysiologic
response to brain ischemic damage. Measurements of rel-
ative CBF showed that tMCAO caused a reduction in
cortical perfusion throughout the ischemic period that
was similar in the EP2-/- and drug-treated mice to that in
their corresponding controls, suggesting that neither
genetic deletion nor pharmacologic activation of the EP2
receptor affected the severity of the ischemic insult.
Thus, our findings indicate a protective role for EP2 by
mechanisms that are likely other than those involving
cerebrovascular effects. Moreover, no significant differ-
ences were observed in body temperature or MABP.
EP2-/- mice that underwent tMCAO or pMCAO had
greater neurologic disability and infarct size than did WT
mice. Although compensatory pathways might occur in
the knockout animals, we show here that WT mice that
received the two higher doses of the EP2 agonist ONO-
AE1-259-01 before tMCAO had significantly less severe
Figure 3 EP2 receptor deletion increases neurologic deficit 
scores and infarct volume in mice subjected to tMCAO. Mice were 
subjected to 90-min tMCAO and evaluated for neurologic deficits at 4 
days. After being scored, the mice were sacrificed, and brain infarction 
was estimated by TTC staining. (A) Representative photographs show 
infarcted brain slices from WT (left) and EP2-/- (right) mice. (B) The bar 
graph shows the corrected cortical, striatal, and hemispheric infarct 
volumes of WT and EP2-/- mice. The infarct size was significantly larger 
in EP2-/- (n = 14) than in WT mice (n = 9). (C) Neurologic deficit scores at 
4 days after ischemia were significantly higher in EP2-/- mice than in WT 
mice, indicating more neurologic dysfunction. **P < 0.01.
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neurologic deficits and less infarct damage, supporting
observations that EP2 receptors are beneficial in excito-
toxicity [8] and in ischemic stroke [9].
Previous reports have shown that the EP2 receptor elic-
its neuroprotective effects under conditions of excitotox-
icity and oxygen-glucose deprivation by increasing
intracellular levels of cAMP and activating PKA signaling
[9,10]. We have also previously reported that pharmaco-
logic activation of EP2 receptors leads to neuroprotection
via the cAMP-PKA pathway [22]. Moreover, the pharma-
cologic stimulation of EP4/EP3 receptors affords protec-
tion by increasing intracellular levels of cAMP and
through activation of the ERK pathway [13]. These cAMP
cascades can provide protection for example by: (1)
reducing the release of endoplasmic Ca2+ through the
inositol triphosphate receptor [23], (2) inhibiting the
expression of adhesion molecules [24], (3) suppressing
the activity of neuronal nitric oxide synthase [25], (4)
stimulating cAMP response element binding (CREB)
[26], and (5) stimulating the high-affinity glutamate
transporter [27]. Interestingly, ONO-AE1-259-01 has
been suggested to elevate cAMP and inhibit expression of
inflammatory molecules such as ICAM-1 and B7.2
(CD86) [28,29], and such inflammatory molecules affect
stroke outcomes [30,31]. The exact cascade in vivo is
likely to be much more elaborate than what we can begin
to address in isolated neuronal cultures, especially con-
sidering the complexity of the different cells and interac-
tions between them and their environment (blood flow,
oxygenation, inflammation, etc) over time. The signaling
pathways of these molecules and kinases are continually
expanding (kinome-phosphorylome projects [32]), with
many branches that link to other pathways. Therefore,
the complete cascade of events that takes place within
any given cell based on its location with respect to the
infarct is likely to differ substantially. Indeed, it is highly
probable that the neuroprotection provided by EP2 stim-
ulation results from a combination of pathways rather
than a single one. For these reasons, we have first focused
here on demonstrating that in the brain, stimulating the
EP2 receptors leads to anatomical and behavioral protec-
tion. T o build on our work with the tMCAO model, we
are now endeavoring to confirm that the EP2-selective
agonist is also protective in the pMCAO model and to
address potential targets/biosystems that could begin to
explain some of the steps leading to neuroprotection.
Two previous studies have indicated that activation of
the PGE2 EP2 receptor can protect against excitotoxic
and anoxic injury [9,10]. In one of those studies, the
tMCAO was followed by only 22.5 h of reperfusion, and
no behavioral outcomes were reported. It is important to
document that such ischemic-reperfusion-related change
in the knockout animal is not transient or delayed, and
that it is indeed maintained at later time points. When a
brief ischemic event is followed by reperfusion, a second
phase of injury occurs (potentially mediated by a surge in
inflammatory markers). What's more, over time, endoge-
n o u s  r e p a i r  p a t h w a y s  c a n  b e  a c t i v a t e d .  A l t h o u g h  i t  i s
more challenging to keep a mouse alive for 96 h after
transient ischemia, we selected this extended reperfusion
Table 2: Effect of ONO-AE1-259-01 on Physiologic Parameters
Parameter Vehicle 0.5 nmol 1 nmol 2 nmol
Pre-ischemia
pH 7.31 ± 0.02 7.28 ± 0.47 7.30 ± 0.46 7.25 ± 0.23
PaCO2 43.2 ± 1.8 44.4 ± 2.0 45.2 ± 1.6 43.0 ± 1.3
PaO2 133 ± 5 139 ± 5 130 ± 8 134 ± 9
MABP 78.6 ± 3.9 75.6 ± 1.7 77.4 ± 2.8 72.8 ± 2.5
Ischemia
pH 7.28 ± 0.02 7.29 ± 0.64 7.26 ± 0.03 7.33 ± 0.02
PaCO2 44.0 ± 1.8 43.2 ± 1.5 45.6 ± 2.6 43.16 ± 1.6
PaO2 129 ± 5 133 ± 4 124 ± 6 133 ± 5
MABP 74.4 ± 1.7 76.6 ± 2.5 74.4 ± 1.8 74.8 ± 1.7
Reperfusion
pH 7.26 ± 0.03 7.28 ± 0.05 7.29 ± 0.40 7.28 ± 0.25
PaCO2 43.0 ± 1.8 45.8 ± 1.4 47.2 ± 1.3 44.8 ± 2.7
PaO2 135 ± 9 129 ± 6 126 ± 7 138 ± 9
MABP 74.6 ± 1.3 73.8 ± 1.7 76.0 ± 1.6 74.0 ± 1.6
Measurements were made in arterial blood samples obtained via femoral catheter (n = 5/group).Ahmad et al. Experimental & Translational Stroke Medicine 2010, 2:12
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time because it enables us to document that the protec-
tive role of EP2 is sustained during the entire period. In
the other study, Liu et al. first tested the stroke outcomes
(without behavioral outcomes) in mice subjected to
pMCAO after only 24 h of survival [10] and then a subse-
quent study suggested that misoprostol (which is a poorly
selective mouse EP2 receptor agonist) has a protective
effect against MCAO injury [33]. For reasons similar to
those described above, it is important to determine the
potential contributions of EP2 to neurobehavioral and
ischemic outcomes at later time points; that is why in our
study we selected 7 days. Both of these previous studies
led to the suggestion that activation of the PGE2 EP2
receptor can protect against ischemic injury, although no
data were provided to support this hypothesis. To make
such a conclusion, one needs to test whether selectively
targeting EP2 would result in neuroprotection. Further-
more, it has been suggested that compensatory mecha-
nisms can occur in knockout animals. Therefore, we
chose to directly activate the EP2 receptor with a selective
agonist to complement the findings in knockout mice.
Based on these novel observations, we can conclude
that pharmacologic stimulation of the EP2 receptor with
a selective pharmacologic agent could potentially be used
therapeutically in translational medicine (most likely in
combination with other standard treatments) to limit
brain damage following ischemic stroke.
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Figure 4 Effect of pretreatment with ONO-AE1-259-01 on neuro-
logic deficit scores and infarct volume after 4 days of reperfusion. 
Mice were pretreated with ONO-AE1-259-01 before being subjected 
to 90-min MCAO and 4 days of reperfusion. (A) Images of representa-
tive TTC-stained brain sections. (B) Percent corrected cortical, striatal, 
and hemispheric infarct volumes. (C) Neurologic deficit scores were 
significantly lower in mice treated with 1.0 and 2.0 nmol ONO-AE1-
259-01 than in vehicle-treated mice. n = 9/group; *P < 0.05 compared 
with the vehicle-treated group.
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Figure 5 EP2 receptor deletion increases neurologic deficit 
scores and infarct volume of mice subjected to pMCAO. Seven 
days after being subjected to pMCAO, mice were assessed for neuro-
logic dysfunction and then sacrificed. (A) Representative images show 
TTC-stained infarcted brain slices from WT (left) and EP2-/- (right) mice. 
(B) The bar graph shows the corrected cortical infarct volumes of WT 
and EP2-/- mice. (C) Neurologic deficit scores at 7 days after ischemia 
were significantly higher in EP2-/- mice (n = 7) than in WT mice (n = 8). 
**P < 0.008.
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